---

Subacute Sclerosing Panencephalitis (SSPE)

Etiology

• Defective virus maturation: The measles virus undergoes mutational changes that affect its M (matrix) protein and other envelope proteins, preventing proper virion assembly and budding. The virus cannot escape the cell and spreads only by direct cell-to-cell contact.
• Intracellular concealment: Because no free virus is released, the virus is largely hidden from the immune system despite very high serum and CSF antimeasles antibody titers (notably, antibody to the M protein is frequently absent).
• Epidemiology: SSPE is a rare late complication with a frequency estimated at 1 in 100,000-500,000 measles cases. The annual incidence is <0.1 to 5-6 cases per million in unimmunized populations. It has declined dramatically since measles vaccination was introduced but may rise with increasing vaccine hesitancy.
• Risk factors: Primary measles infection before 2 years of age (highest risk), male sex (M:F ratio ~3:1), immunocompetent host (unlike measles inclusion body encephalitis, which affects immunocompromised patients).
• Latency interval: Median 6-8 years after primary measles infection (range 2-12 years), followed by insidious neurological onset.

---

Clinical Features

General Sequence

Stage-wise Clinical Progression (Jabbour Classification - 4 Stages)

• Decline in school performance and academic ability
• Personality and mood changes, temper outbursts
• Difficulty with language, forgetfulness
• Loss of interest in usual activities
• No obvious neurological signs

• Severe progressive intellectual deterioration
• Myoclonus - repetitive, shock-like jerks (characteristic and often leads to diagnosis)
• Focal and/or generalized seizures
• Ataxia, choreoathetoid or ballistic movements
• Chorioretinitis, visual disturbances
• Spasticity, hyperactive deep tendon reflexes

• Optic atrophy
• Quadriparesis, progressive unresponsiveness
• Autonomic instability
• Akinetic mutism
• Coma ("decerebrate/decorticate" posture)

• Child lies insensate, virtually "decorticated"
• Complete loss of cortical function
• Death typically within 1-3 years of onset

Clinical course is usually steadily progressive to death within 1-3 years. Spontaneous remissions are estimated in ~5% of cases. Acute symptoms with increased intracranial pressure are poor prognostic signs.

---

Histopathology (Pathological Features)

• Cowdry type A eosinophilic intranuclear inclusions in neurons and glial cells - the histopathological hallmark
• Cytoplasmic inclusions also present in neurons (cigar-shaped)
• Destruction of nerve cells, neuronophagia
• Perivenous cuffing by lymphocytes and mononuclear cells
• White matter: degeneration of myelinated fibers (both myelin and axons) + fibrous gliosis ("sclerosing")
• Distribution: cerebral cortex and white matter of both hemispheres + brainstem; cerebellum usually spared
• Electron microscopy shows measles nucleocapsids within inclusion-bearing cells

---

Radiological Features (MRI/CT)

MRI (Investigation of Choice)

• Lesions are asymmetric early, becoming more diffuse with progression
• No contrast enhancement (blood-brain barrier usually intact)
• Brainstem changes appear in later stages
• MRI changes begin in subcortical white matter and spread to the periventricular region

EEG (Critical Diagnostic Tool)

• Pathognomonic pattern: Periodic (every 3-14 seconds, typically 5-8 seconds) bursts of high-voltage, sharp slow-wave complexes (2-3/s) lasting up to 3 seconds, against a background of depressed ("flat") activity
• The periodic complexes are synchronous with the myoclonic jerks
• Early SSPE may show only nonspecific slowing
• These periodic complexes appear prominently in Stage II

CSF Findings

• Acellular (no pleocytosis)
• Normal or mildly elevated protein
• Markedly elevated gamma globulin (>20% of total CSF protein)
• Oligoclonal bands (measles-virus-specific IgG)
• Elevated CSF antimeasles antibody - invariably elevated; CSF/serum ratio confirms intrathecal synthesis
• Antibody to M protein frequently absent

---

Diagnosis

• Clinical: Characteristic clinical stages in a child with history of early measles
• EEG: Periodic high-voltage slow-wave complexes
• CSF: Elevated measles antibody, oligoclonal bands, elevated gamma globulin
• Serum: Very high antimeasles antibody titers
• MRI: T2/FLAIR white matter changes (posterior > anterior early)
• Brain biopsy (if needed): Viral inclusions + measles antigen by immunocytochemistry, viral genome by PCR/in situ hybridization; measles virus can be cultured from brain by special cocultivation techniques

---

Treatment

Antiviral/Immunomodulatory Therapy

Symptomatic Treatment

• Anticonvulsants: e.g., Levetiracetam (shown to improve myoclonus and encephalopathy symptomatically)
• Seizure control, management of spasticity, nutritional support

Treatment Monitoring

• Laboratory endpoint: eradication of detectable measles antigen from CSF
• Risks of prolonged/repeated interferon: meningitis, IFN-α-induced encephalopathy, upper and lower motor neuron toxicity

Prevention (Most Effective Intervention)

• MMR vaccine (measles, mumps, rubella) at 12-15 months, second dose at 4-6 years (MMRV is the quadrivalent option)
• Vaccination essentially eliminates the risk of SSPE; the disease has practically disappeared in countries with high measles vaccination coverage

---

Summary Table

---

• Bradley & Daroff's Neurology in Clinical Practice (primary)
• Harrison's Principles of Internal Medicine 22E (2025)
• Adams & Victor's Principles of Neurology 12E
• Robbins, Cotran & Kumar Pathologic Basis of Disease
• Goldman-Cecil Medicine (International Ed.)

---

Subacute Sclerosing Panencephalitis (SSPE) - Complete Review

---

1. DEFINITION

---

2. ETIOLOGY AND PATHOGENESIS

Causative Agent

• Measles virus (Paramyxoviridae family, genus Morbillivirus) - a single-stranded, negative-sense RNA virus
• The virus responsible is wild-type (not vaccine strain); vaccination is protective

Why Does the Virus Persist?

Key: The virus is concealed from the immune system inside cells. Despite the host mounting massive antimeasles antibody responses (highest measured antibody titers in any known condition), the virus cannot be cleared.

Epidemiology

• Incidence: ~1/100,000-500,000 measles cases; 4-11 per 100,000 measles survivors; 0.1-5 per million in unimmunized populations
• ~5 cases/year reported in the USA currently; several times higher in resource-limited countries
• Age at diagnosis: 85% between 5-15 years old
• Sex: Males predominate - male:female ratio = 3:1 (consistently across case series)
• Latent interval: Median 6-8 years after primary measles (range 2-12 years; Goldman-Cecil states 7-10 years)
• Primary infection age: Most had measles before age 2 years (key risk factor - early-life infection before full immune maturation)
• Incidence has declined dramatically with measles vaccination but may rise again with vaccine hesitancy and measles resurgence

---

3. CLINICAL FEATURES

Jabbour Staging System (4 Stages)

---

Stage I - Behavioral / Mental Changes ("Insidious Stage")

• Insidious onset of personality change - irritability, temper outbursts, emotional lability
• Decline in school performance - difficulty concentrating, memory lapses
• Difficulty with language - word-finding problems
• Social withdrawal, loss of interest in usual activities
• No myoclonus, no seizures at this stage
• Cognitive symptoms mimic psychiatric illness (depression, behavioral disorder)
• Often misdiagnosed at this stage - psychiatric referral is common

Mnemonic: "Bad Student" stage - behavioral + school decline

---

Stage II - Neurological / Motor Complications

• Myoclonus - characteristic repetitive, shock-like muscle jerks; often symmetrical; may be triggered by sensory stimuli in advanced Stage II; this symptom typically brings the patient to medical attention
• Seizures - focal and/or generalized; may be refractory
• Progressive intellectual deterioration - severe dementia
• Ataxia - cerebellar gait disturbance
• Choreoathetoid or ballistic movements, extrapyramidal signs
• Chorioretinitis - visual disturbances; macular lesion appears white/grey-white, resolves to leave scarring and irregular RPE atrophy
• Papilloedema, nystagmus, optic neuritis may occur
• Spasticity develops, hyperactive deep tendon reflexes
• Posterior uveitis is common and may be the presenting feature (before obvious CNS involvement)
• The EEG periodic complexes become evident at this stage (synchronous with myoclonic jerks)

The classic Rademecker complexes on EEG are most prominent in Stage II

---

Stage III - Advanced / Pre-terminal ("Coma Stage")

• Akinetic mutism - patient awake but completely unresponsive
• Quadriparesis
• Progressive unresponsiveness
• Optic atrophy - from prior chorioretinitis/optic neuritis
• Autonomic instability - thermoregulatory dysfunction, hyperhidrosis
• Dysphagia, incontinence
• Extensor plantar responses (Babinski sign)
• Acute episodes with raised intracranial pressure - poor prognostic sign

---

Stage IV - Vegetative / Terminal State

• Child lies insensate - virtually "decorticated" or "decerebrate"
• Complete loss of cortical function
• Progressive inanition
• Superinfection (aspiration pneumonia, UTI, decubitus ulcers)
• Metabolic imbalances
• Death - within 1-3 years of onset in most cases

Prognosis

• Course is uniformly fatal in most cases
• Majority die within 1-3 years of symptom onset
• Spontaneous remissions: estimated ~5% (usually incomplete and temporary)
• Adult-onset SSPE: older patients (one series mean age 21 years, oldest 43); visual disturbances and extrapyramidal features more prominent, raising concern for prion disease; myoclonus present early

Ophthalmic Features (from Kanski's Ophthalmology 10E)

• Posterior uveitis may be the presenting feature before CNS symptoms
• Chorioretinitis with macular involvement - white/grey-white macular lesion
• Ischaemic retinal vein occlusion secondary to vasculitis (rare)
• Papilloedema, optic neuritis, nystagmus
• Congenital measles: cataract, retinopathy possible

---

4. STAGES - SUMMARY TABLE

---

5. INVESTIGATIONS AND DIAGNOSTIC FEATURES

A. EEG - Pathognomonic Pattern ("Rademecker Complexes")

• Periodic bursts of high-voltage, sharp, slow-wave complexes (2-3 Hz), lasting up to 3 seconds
• Occur at regular intervals of 4-14 seconds (typically every 5-8 seconds)
• Against a background of depressed/attenuated ("flat") activity
• Synchronous with myoclonic jerks - this correlation is virtually diagnostic
• Early in disease: only nonspecific slowing
• Stage II: classic periodic pattern fully developed
• Late/terminal: nearly isoelectric

B. CSF Analysis

C. Serum

• Very high antimeasles antibody titers (among the highest ever measured in any infectious disease)
• Antibody to M protein frequently absent (marker of defective virus)

D. Virological Confirmation

• Measles virus can be cultured from brain tissue using special cocultivation techniques
• Immunocytochemistry: viral antigen in brain tissue
• In situ hybridization or PCR: viral genome detection in brain or CSF
• Brain biopsy: Cowdry type A inclusions + viral antigen

E. Diagnostic Criteria (Clinical)

1. Periodic EEG complexes (Rademecker complexes)
2. Elevated CSF gamma globulin + oligoclonal bands
3. Elevated measles antibody titers in serum and CSF

---

6. RADIOLOGICAL FEATURES

MRI (Investigation of Choice)

Distribution of Findings (461 cases):

Stage-wise MRI Evolution:

• Often normal
• First changes: T2/FLAIR hyperintensities in subcortical white matter of posterior hemispheres (parieto-occipital region)
• Asymmetric, patchy

• T2/FLAIR lesions extend anteriorly
• Cortical and subcortical involvement in temporal, parietal, frontal lobes
• Periventricular white matter involvement develops
• No/minimal contrast enhancement (BBB relatively intact)

• Lesions spread to involve brainstem
• Deep gray matter lesions - basal ganglia, thalamus
• Progressive cerebral atrophy - cortical and subcortical
• Confluent white matter changes resembling leukodystrophy
• Diffusion restriction may be seen (cytotoxic edema in acute active lesions)

Key MRI Characteristics:

• Posterior (parieto-occipital) > anterior distribution early
• White matter > gray matter early; both involved later
• No/minimal contrast enhancement (distinguishes from other encephalitides)
• Diffusion restriction when present = active demyelination/cytotoxic edema
• Progressive atrophy on serial imaging
• Cerebellum usually spared (classic teaching from Adams & Victor)

Radiological Mimics (Garg 2026):

CT Scan

• Less sensitive than MRI
• May be normal early
• Later: low-density white matter lesions, cerebral atrophy
• CT used in 12.6% of cases in systematic review (mostly resource-limited settings)

---

7. PATHOLOGY (Histopathology)

Macroscopic

• Brain atrophy, firm white matter (sclerosing)
• Grey and white matter of both cerebral hemispheres and brainstem affected
• Cerebellum usually spared

Microscopic (H&E)

• Cowdry type A eosinophilic intranuclear inclusions in neurons and glial cells - hallmark of SSPE
• Cigar-shaped cytoplasmic inclusions in neurons
• Destruction of nerve cells, neuronophagia
• Perivenous cuffing by lymphocytes and mononuclear cells
• White matter: demyelination of axons and myelin sheaths
• Fibrous gliosis (hence "sclerosing")
• Both gray matter (cortex) and white matter involved

Electron Microscopy

• Measles nucleocapsids visible within inclusion-bearing cells

---

8. DIFFERENTIAL DIAGNOSIS

---

9. TREATMENT

A. Antiviral/Immunomodulatory Therapy

B. Symptomatic Treatment

C. Treatment Monitoring

• Laboratory endpoint: Eradication of detectable measles antigen from CSF
• Serial clinical assessment and EEG
• Risks of prolonged IFN therapy: meningitis, IFN-induced encephalopathy, upper and lower motor neuron toxicity

D. Spontaneous Remission

• Approximately 5% of cases show spontaneous (usually temporary) improvement - always consider when evaluating treatment response

---

10. PREVENTION

• MMR vaccine (Measles-Mumps-Rubella) - most important intervention
  • First dose: 12-15 months of age
  • Second dose: 4-6 years of age
  • Also available as MMRV (quadrivalent: measles, mumps, rubella, varicella)
• Measles vaccination has virtually eliminated SSPE in countries with high coverage
• Rising vaccine hesitancy and measles resurgence (including in the USA) may cause an increase in SSPE cases in the coming decades (Harrison's 22E warning)
• Post-exposure prophylaxis with immunoglobulin within 6 days of measles exposure (especially for children <1 year, pregnant women, immunocompromised)

---

11. COMPLETE DIAGNOSTIC CRITERIA SUMMARY

1. Characteristic clinical picture - Progressive neurological deterioration in a child with history of early measles
2. Periodic EEG - High-voltage slow-wave complexes every 5-8 seconds (Rademecker complexes)
3. CSF: Elevated gamma globulin (>20%), oligoclonal bands, acellular
4. Serum and CSF antimeasles antibody: Invariably elevated
5. Confirmatory (if needed): Brain biopsy - Cowdry A inclusions; PCR for measles genome; viral antigen by immunocytochemistry; viral culture by cocultivation

---

12. OVERVIEW TABLE

---

• Bradley & Daroff's Neurology in Clinical Practice - primary neurology reference
• Harrison's Principles of Internal Medicine 22E (2025, McGraw Hill)
• Adams & Victor's Principles of Neurology 12E
• Robbins, Cotran & Kumar Pathologic Basis of Disease
• Goldman-Cecil Medicine (International Edition)
• Jawetz, Melnick & Adelberg's Medical Microbiology 28E
• Sherris & Ryan's Medical Microbiology 8E
• Kanski's Clinical Ophthalmology: A Systematic Approach 10E

• Garg RK et al. "The neuroimaging spectrum of SSPE: a systematic review." Neuroradiology 2026 (PMID 42113281) - comprehensive MRI data from 461 cases confirming predominant posterior bilateral white matter involvement with stage-evolving pattern
• Garg RK et al. "Psychiatric manifestations in SSPE." CNS Spectr 2024 (PMID 38282559) - confirms psychiatric features are common at Stage I and frequently delay diagnosis